| Rudick RA, Fisher E
Do interferon beta-1b and glatiramer acetate grow brain? [Comment, Letter]
Lancet Neurol 2009 Dec; 8(12):1085-6; author reply 1086-7.
Full Citation | Find Related Articles |
| Moraal B, Pohl C, Uitdehaag BM, et al.
Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study. [Journal Article, Research Support, Non-U.S. Gov't]
Arch Neurol 2009 Nov; 66(11):1345-52.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |
| Szilasiová J, Gdovinová Z, Jautová J, et al.
Cutaneous Vasculitis Associated With Interferon beta-1b Treatment for Multiple Sclerosis. [JOURNAL ARTICLE]
Clin Neuropharmacol 2009 September/October; 32(5):301-303.
Abstract | Full Citation |
| Festa ED, Hankiewicz K, Kim S, et al.
Serum levels of CXCL13 are elevated in active multiple sclerosis. [JOURNAL ARTICLE]
Mult Scler 2009 Oct 5.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |
| Montalban X, Sastre-Garriga J, Tintoré M, et al.
A single-centre, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. [JOURNAL ARTICLE]
Mult Scler 2009 Sep 29.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |
| Sormani MP, Rovaris M, Comi G, et al.
A reassessment of the plateauing relationship between T2 lesion load and disability in MS. [JOURNAL ARTICLE]
Neurology 2009 Sep 30.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |
| Pittock SJ
Uncertain BENEFIT of early interferon beta-1b treatment. [LETTER]
Lancet Neurol 2009 Sep 10.
Full Citation | Publisher Full Text | Find Related Articles |
| Kappos L, Freedman MS, Polman CH, et al.
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. [JOURNAL ARTICLE]
Lancet Neurol 2009 Sep 10.
Abstract | Full Citation | Find Related Articles |
| Goldberg LD, Edwards NC, Fincher C, et al.
Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. [Journal Article]
J Manag Care Pharm 2009 Sep; 15(7):543-55.
Abstract | Full Citation | Find Related Articles |
| Simó M
[Therapy of multiple sclerosis] [English Abstract, Journal Article]
Neuropsychopharmacol Hung 2009 Mar; 11(1):23-6.
Abstract | Full Citation | Find Related Articles |
  |
